Effect of angiotensin converting enzyme inhibition on platelet angiotensin II content. 1988

A Santucci, and C Ferri, and R Leonetti Luparini, and M A Del Porto, and C De Angelis, and C Ficara, and F Balsano
Institute of I Clinica Medica, University of Rome La Sapienza, Italy.

The effect of captopril treatment on platelet angiotensin II levels was evaluated in 12 patients with essential hypertension. Captopril significantly lowered (p less than 0.01) mean arterial blood pressure in seven patients (Group 1) and was ineffective in five (Group 2). In Group 1, a marked decrease in plasma angiotensin II levels in both the supine (from 5.5 +/- 0.5 to 2.8 +/- 0.9 pg/ml) and the upright positions (from 17.5 +/- 4.7 to 3.9 +/- 1.6 pg/ml; p less than 0.0025) and a significant increase in platelet angiotensin II levels (from 10.5 +/- 5.3 to 22.4 +/- 17 pg/ml; p less than 0.05) after captopril treatment was observed. In Group 2, no variation was found in plasma angiotensin II levels, whereas platelet angiotensin II levels increased slightly (from 10.8 +/- 3.1 pg/ml to 16.9 +/- 5.2 pg/ml; NS). These findings suggest that the decrease in plasma angiotensin II levels can lead to an increase in platelet angiotensin II receptors or can lead to angiotensin II production in platelets through activation of a feedback mechanism. The second hypothesis suggests that platelets have alternative enzymatic pathways leading to angiotensin II production not inhibited by captopril.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D002216 Captopril A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline,Capoten,Lopirin,SQ-14,225,SQ-14,534,SQ-14225,SQ-14534,SQ 14,225,SQ 14,534,SQ 14225,SQ 14534,SQ14,225,SQ14,534,SQ14225,SQ14534
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine

Related Publications

A Santucci, and C Ferri, and R Leonetti Luparini, and M A Del Porto, and C De Angelis, and C Ficara, and F Balsano
May 2005, Circulation,
A Santucci, and C Ferri, and R Leonetti Luparini, and M A Del Porto, and C De Angelis, and C Ficara, and F Balsano
January 2007, Journal of human hypertension,
A Santucci, and C Ferri, and R Leonetti Luparini, and M A Del Porto, and C De Angelis, and C Ficara, and F Balsano
June 1992, The Journal of international medical research,
A Santucci, and C Ferri, and R Leonetti Luparini, and M A Del Porto, and C De Angelis, and C Ficara, and F Balsano
June 1974, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
A Santucci, and C Ferri, and R Leonetti Luparini, and M A Del Porto, and C De Angelis, and C Ficara, and F Balsano
April 1996, Journal of clinical pharmacology,
A Santucci, and C Ferri, and R Leonetti Luparini, and M A Del Porto, and C De Angelis, and C Ficara, and F Balsano
September 1997, The Journal of urology,
A Santucci, and C Ferri, and R Leonetti Luparini, and M A Del Porto, and C De Angelis, and C Ficara, and F Balsano
April 1987, The American journal of cardiology,
A Santucci, and C Ferri, and R Leonetti Luparini, and M A Del Porto, and C De Angelis, and C Ficara, and F Balsano
September 1980, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
A Santucci, and C Ferri, and R Leonetti Luparini, and M A Del Porto, and C De Angelis, and C Ficara, and F Balsano
November 1990, Hypertension (Dallas, Tex. : 1979),
A Santucci, and C Ferri, and R Leonetti Luparini, and M A Del Porto, and C De Angelis, and C Ficara, and F Balsano
March 2008, Digestive diseases and sciences,
Copied contents to your clipboard!